Autistic Disorder

The grounding supports a multifactorial neurodevelopmental basis rather than a single cause. Review abstracts emphasize genetic and epigenetic mutations, interactions with transcription factors, and chromatin remodeling processes in brain neurons. The literature also discusses biological sex as a factor that may modify prevalence estimates, but not as a proven cause.

The literature describes neurobiological alterations involving gene transcription, RNA and non-coding RNA translation, abnormal synaptic signaling pathways, and epigenetic post-translational mechanisms. One review also links ASD to effects on inhibitory and excitatory synaptic structures and to brain-area involvement. Resting-state EEG studies report differences across canonical frequency bands, consistent with altered brain network function.

The supplied grounding supports biological sex as a factor associated with differences in prevalence estimates. It also notes that sociodemographic status, ethnicity/race, and nativity have been examined as potential modifiers of prevalence, but does not establish them as risk factors. No other specific risk factors are supported by the grounding.

The grounding supports therapy at a general level but does not provide specific treatment recommendations. It indicates that ASD has no clear diagnostic markers and no specifically targeted medications, and that the literature discusses novel pharmacological therapy alongside multidisciplinary care. The treatment modality level supported here is behavioral and multidisciplinary management, with pharmacologic approaches remaining non-specific and investigational in the supplied material.